# OnCo record paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022" ;
  schema:name "Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update"@en ;
  schema:description "The US oncology society's 2022 rules on which tests to run before choosing drugs for metastatic breast cancer: PD-L1 for pembrolizumab, germline BRCA for PARP inhibitors, and no routine test for TROP2 or for tumour DNA in blood."@en ;
  schema:url <https://onco.cc/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.01063>, <https://pubmed.ncbi.nlm.nih.gov/35759724/> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.01063> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Henry NL, Somerfield MR, Dayao Z, et al." ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/trop2/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/cps/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/jco/> .